Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.
Aarkstore.com announces, The Latest market research report is available inits vast collection:Non-Small Cell Lung Cancer –...
company and industry-specific sources.- Coverage of products based on various stages of development ranging fromdiscovery ...
Bristol-Myers Squibb Company 160Boehringer Ingelheim GmbH 161F. Hoffmann-La Roche Ltd. 162Kyowa Hakko Kirin Co., Ltd. 163A...
Chronic Lymphocytic Leukemia (CLL) – Pipeline Review, H2 2012 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) ...
Upcoming SlideShare
Loading in …5
×

Non small cell lung cancer – pipeline review, h2 2012

707 views

Published on

Aarkstore Enterprise-Non small cell lung cancer – pipeline review, h2 2012

Published in: Business
  • Be the first to comment

  • Be the first to like this

Non small cell lung cancer – pipeline review, h2 2012

  1. 1. Aarkstore.com announces, The Latest market research report is available inits vast collection:Non-Small Cell Lung Cancer – Pipeline Review, H2 2012You can also request for sample page of above mention reports onsample@aarkstore.comSummaryGlobal Markets Direct’s, Non-Small Cell Lung Cancer - Pipeline Review, GlobalMarkets Direct’s, Non-Small Cell Lung Cancer - Pipeline Review, H2 2012, providesan overview of the indication’s therapeutic pipeline. This report providesinformation on the therapeutic development for Non-Small Cell Lung Cancer,complete with latest updates, and special features on late-stage and discontinuedprojects. It also reviews key players involved in the therapeutic development forNon-Small Cell Lung Cancer. Non-Small Cell Lung Cancer - Pipeline Review, HalfYear is built using data and information sourced from Global Markets Direct’sproprietary databases, Company/University websites, SEC filings, investorpresentations and featured press releases from company/university sites andindustry-specific third party sources, put together by Global Markets Direct’s team.Note*: Certain sections in the report may be removed or altered based on theavailability and relevance of data for the indicated disease.Scope- A snapshot of the global therapeutic scenario for Non-Small Cell Lung Cancer.- A review of the Non-Small Cell Lung Cancer products under development bycompanies and universities/research institutes based on information derived from
  2. 2. company and industry-specific sources.- Coverage of products based on various stages of development ranging fromdiscovery till registration stages.Reasons to buy- Identify and understand important and diverse types of therapeutics underdevelopment for Non-Small Cell Lung Cancer.- Identify emerging players with potentially strong product portfolio and designeffective counter-strategies to gain competitive advantage.Table of contents:List of Tables 25List of Figures 33Introduction 34Global Markets Direct Report Coverage 34Non-Small Cell Lung Cancer Overview 35Therapeutics Development 36An Overview of Pipeline Products for Non-Small Cell Lung Cancer 36Non-Small Cell Lung Cancer Therapeutics under Development by Companies 38Non-Small Cell Lung Cancer Therapeutics under Investigation byUniversities/Institutes 50Late Stage Products 72Comparative Analysis 72Mid Clinical Stage Products 73Comparative Analysis 73Early Clinical Stage Products 74Comparative Analysis 74Discovery and Pre-Clinical Stage Products 75Comparative Analysis 75Non-Small Cell Lung Cancer Therapeutics – Products under Development byCompanies 76Non-Small Cell Lung Cancer Therapeutics – Products under Investigation byUniversities/Institutes 101Companies Involved in Non-Small Cell Lung Cancer Therapeutics Development 160
  3. 3. Bristol-Myers Squibb Company 160Boehringer Ingelheim GmbH 161F. Hoffmann-La Roche Ltd. 162Kyowa Hakko Kirin Co., Ltd. 163Abbott Laboratories 164Biogen Idec Inc. 165Helix BioPharma Corp. 166Amgen Inc. 167Sanofi-Aventis 168List of FiguresList of Tables are also include.For more related Reports Plz follow The link:Pipeline Review, H2 2012http://www.aarkstore.com/search/viewresults.asp?search=Pipeline Review, H22012&PubId=&pagenum=1 Liver Cancer – Pipeline Review, H2 2012 Non-Small Cell Lung Cancer – Pipeline Review, H2 2012 Asthma – Pipeline Review, H2 2012 Multiple Sclerosis – Pipeline Review, H2 2012 Gastrointestinal Tract Cancer – Pipeline Review, H2 2012 Diabetes – Pipeline Review, H2 2012
  4. 4. Chronic Lymphocytic Leukemia (CLL) – Pipeline Review, H2 2012 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline Review,H2 2012 Graft Versus Host Disease (GVHD) – Pipeline Review, H2 2012 Malaria – Pipeline Review, H2 2012 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections – Pipeline Review,H2 2012 Dermatitis – Pipeline Review, H2 2012Search More Reports Related to This Category :Pharmaceuticals and Healthcarehttp://www.aarkstore.com/search/viewresults.asp?search=Pharmaceuticals andHealthcare&PubId=&pagenum=1For More details Plz do contact :Aarkstore EnterpriseLavanyaPhone:08149852585Email: enquiry@aarkstore.com

×